We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies Procedures to Report Biologics Manufacturing Deviations
FDA Clarifies Procedures to Report Biologics Manufacturing Deviations
October 20, 2006
The FDA has issued a guidance detailing the correct steps to take when an event occurs that may affect the safety, purity or potency of products in an effort to help biological product manufacturers report deviations from current good manufacturing practices (cGMPs).